Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218145

SCHEMBL23218145

SCHEMBL23218145

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C)oc2c(C3CC3)cc(Cl)cc12

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 3/20 0.37
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ POLB P06746 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ TSHR P16473 3/20 0.35
▸ PKM P14618 1/20 0.34
▸ CTDSP1 Q9GZU7 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ PTGDR2 Q9Y5Y4 2/20 0.34
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852770 1.00 PTGS2 (0.37) PTGS2MEN1KMT2AKDM4EPOLB
SCHEMBL29853001 0.90 MEN1 (0.36) PTGS2MEN1KMT2AKDM4EPOLB
SCHEMBL29591409 0.90 MEN1 (0.36) PTGS2MEN1KMT2AKDM4EPOLB
SCHEMBL23218374 0.90 MEN1 (0.36) PTGS2MEN1KMT2AKDM4EPOLB
SCHEMBL29852881 0.86 PTGS2 (0.39) PTGS2MEN1KMT2APOLBTSHR
SCHEMBL23218450 0.86 PTGS2 (0.39) PTGS2MEN1KMT2APOLBTSHR
SCHEMBL23218501 0.85 CNR1 (0.37) PTGS2MEN1KMT2AKDM4EPOLB
SCHEMBL29852727 0.85 CNR1 (0.37) PTGS2MEN1KMT2AKDM4EPOLB
SCHEMBL23218114 0.83 CFD (0.41) MEN1KMT2AKDM4E
SCHEMBL29852472 0.83 CFD (0.41) MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 PTGS2 3426/4885MEN1 757/4885KMT2A 4413/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PTGS2 1208/4885MEN1 1819/4885KMT2A 4445/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTGS2 2338/4885MEN1 548/4885KMT2A 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.